8-K: American Oncology Network Reports 11.3% Revenue Growth for Fiscal Year 2023 Despite Net Loss

American Oncology Network (AON) announced a significant 11.3% revenue increase for fiscal year 2023, driven by patient encounter growth, but reported a net loss due to various factors including transaction expenses and billing system transition costs.

Summary

• American Oncology Network (AON) reported its financial results for the fiscal year ending December 31, 2023.
• The company's revenue for the full year reached $1,279.2 million, an 11.3% increase compared to $1,149.7 million in 2022.
• This revenue growth was primarily driven by a 7.9% increase in patient encounters.
• However, AON experienced a net loss of $63.2 million for the year, compared to a net income of $2.6 million in the previous year.
• The net loss was primarily due to a $27.9 million increase in transaction expenses related to the company's business combination, $20.7 million in non-recurring accounts receivable reserves, and other non-cash expenses.
• For the fourth quarter of 2023, revenue was $324.2 million, a 7.9% increase year-over-year, with a 9.5% increase in patient encounters.
• The fourth quarter net loss was $22.4 million, compared to a net income of $1.4 million in the same period of 2022, largely due to the $20.7 million in accounts receivable reserves.
• Adjusted EBITDA for the full year was $18.0 million, comparable to 2022, while the fourth quarter adjusted EBITDA was $5.0 million, down from $8.0 million in the prior year quarter due to higher drug costs.
• As of December 31, 2023, AON had total liquidity of $105.3 million, including cash, short-term marketable securities, and borrowing capacity.

Sentiment

Score: 4

Explanation: While the revenue growth is positive, the significant net loss and decrease in adjusted EBITDA, along with the non-recurring expenses, create a negative sentiment. The company's future outlook is positive, but the current financial results are concerning.

Positives

• AON achieved a significant 11.3% increase in revenue for fiscal year 2023, reaching $1,279.2 million.
• Patient encounter growth was strong, with a 7.9% increase for the full year and 9.5% in the fourth quarter.
• The company successfully transitioned to a new enterprise revenue cycle platform, which is expected to improve future operations.
• AON maintains a solid liquidity position with $105.3 million available as of December 31, 2023.

Negatives

• AON reported a net loss of $63.2 million for fiscal year 2023, a significant decrease from the $2.6 million net income in 2022.
• The fourth quarter net loss was $22.4 million, a substantial drop from the $1.4 million net income in the same period of 2022.
• Adjusted EBITDA decreased in the fourth quarter to $5.0 million, down from $8.0 million in the prior year quarter.
• The company incurred $20.7 million in non-recurring accounts receivable reserves due to the transition to a new billing system.

Risks

• The company's transition to a new billing system resulted in significant non-recurring expenses and a decrease in revenue per encounter.
• Increased drug costs negatively impacted the fourth quarter adjusted EBITDA.
• Transaction expenses related to the business combination significantly contributed to the net loss for the year.
• The company's financial performance is subject to various risks and uncertainties, as detailed in their Form 10-K.

Future Outlook

The company believes that AON, as the only true national oncology platform, will be the destination of choice for community oncology practices looking to continue to grow their practices well into the future. The company also made significant investments in its platform of services, including a new enterprise revenue cycle platform, to ensure it is well-positioned for the future.

Management Comments

• Todd Schonherz, AON chief executive officer, stated that the leadership team is very proud of the growth and accomplishments in 2023.
• He highlighted the impressive growth across all aspects of the business, including a $129.5 million increase in top-line revenue.
• He also noted the strategic investment in the new enterprise revenue cycle platform, which helps AON navigate disruptions like the Change Healthcare outage.

Industry Context

AON operates in the community-based oncology management sector, which is experiencing growth and consolidation. The company's focus on physician-led practices and its national platform positions it to compete effectively in this market. The transition to a new revenue cycle platform is a strategic move to improve efficiency and navigate industry challenges.

Comparison to Industry Standards

• While AON's revenue growth of 11.3% is strong, the net loss of $63.2 million is a concern compared to other established healthcare providers.
• The transition to a new billing system and the associated costs are not uncommon in the healthcare industry, but the magnitude of the impact on AON's financials is significant.
• Companies like McKesson and Cardinal Health, which provide services to healthcare providers, often report more stable earnings, but they also operate in different segments of the healthcare market.
• AON's adjusted EBITDA of $18 million is relatively low compared to larger, more established healthcare networks, indicating potential challenges in profitability.

Related Party Transactions

• The document includes related party inventory expense of $1,056,343, $922,148, and $718,675 for the years ended December 31, 2023, 2022, and 2021, respectively.
• The document includes related party rent of $2,716, $2,643, and $2,319 for the years ended December 31, 2023, 2022, and 2021, respectively.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the decrease in adjusted EBITDA.
• Employees may be impacted by the company's restructuring and cost-cutting measures.
• Customers (patients) may benefit from the company's investments in its platform and services.
• Suppliers may be affected by changes in the company's purchasing patterns.
• Creditors may be concerned about the company's financial performance and its ability to repay debts.

Next Steps

• AON will host a conference call on March 28, 2024, to discuss the fourth quarter 2023 results.
• The company will continue to focus on growing its network and improving its platform of services.

Key Dates

Keywords

oncology, revenue, EBITDA, financial results, patient encounters, healthcare, billing system, net loss, AON, American Oncology Network